Last reviewed · How we verify

NCT05951101

Zenith LAA Occlusion System

Recruiting now NA Last updated 16 October 2024
What this trial tests

NA trial testing Zenith LAA Occlusion System in Atrial Fibrillation in 10 participants. Currently enrolling.

Timeline
28 March 2024
Primary endpoint
31 January 2025
31 December 2025

Quick facts

Lead sponsorAuriGen Medical Ltd
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposedevice feasibility
Enrollment10
Start date28 March 2024
Primary completion31 January 2025
Estimated completion31 December 2025
Sites3 locations across New Zealand, Australia

Drugs / interventions tested

Conditions studied

Sponsor

AuriGen Medical Ltd

Who can join

18 and older, any sex, with Atrial Fibrillation or Left Atrial Appendage. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Demonstrate the safety and performance of the Zenith LAA Occlusion System and procedure to occlude the Left Atrial Appendage (LAA) from the left atrium (LA) using a minimally invasive technique. Indication - LAA closure in patients with non-valvular atrial fibrillation, with an ostial diameter between 18 mm and 26 mm

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05951101.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing